162 related articles for article (PubMed ID: 38406785)
21. Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance.
Dokmanovic M; Shen Y; Bonacci TM; Hirsch DS; Wu WJ
Mol Cancer Ther; 2011 Jun; 10(6):917-28. PubMed ID: 21487052
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer.
Tataroglu Ozyukseler D; Basak M; Ay S; Koseoglu A; Arıcı S; Oyman A; Sürmeli H; Turan M; Turan N; Odabaş H; E Yıldırım M
J Oncol Pharm Pract; 2021 Apr; 27(3):547-554. PubMed ID: 32423326
[TBL] [Abstract][Full Text] [Related]
23. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C
Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523
[TBL] [Abstract][Full Text] [Related]
24. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.
Wong H; Leung R; Kwong A; Chiu J; Liang R; Swanton C; Yau T
Oncologist; 2011; 16(11):1535-46. PubMed ID: 22020213
[TBL] [Abstract][Full Text] [Related]
25. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
26. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y; Zi X; Pollak M
Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
[TBL] [Abstract][Full Text] [Related]
28. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
Somlo G; Martel CL; Lau SK; Frankel P; Ruel C; Gu L; Hurria A; Chung C; Luu T; Morgan R; Leong L; Koczywas M; McNamara M; Russell CA; Kane SE
Breast Cancer Res Treat; 2012 Feb; 131(3):899-906. PubMed ID: 22042372
[TBL] [Abstract][Full Text] [Related]
30. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
[TBL] [Abstract][Full Text] [Related]
31. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
[TBL] [Abstract][Full Text] [Related]
32. Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.
Deb TB; Zuo AH; Barndt RJ; Sengupta S; Jankovic R; Johnson MD
Breast Cancer Res Treat; 2015 Apr; 150(2):347-61. PubMed ID: 25773930
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
34. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
35. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
36. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
Xu C; Wang Y; Hong Y; Yao R; Wu L; Shen X; Qu Y; Zhang Z; Zhu W; Yang Y; Chen W; Zhou Y; Liang Z
Breast Cancer Res Treat; 2023 Jun; 199(3):603-615. PubMed ID: 37084155
[TBL] [Abstract][Full Text] [Related]
37. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH
Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y; Zi X; Zhao Y; Mascarenhas D; Pollak M
J Natl Cancer Inst; 2001 Dec; 93(24):1852-7. PubMed ID: 11752009
[TBL] [Abstract][Full Text] [Related]
39. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
40. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
